Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.
about
Current global status & impact of human papillomavirus vaccination: Implications for IndiaEurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines.Vaccination to prevent human papillomavirus infections: From promise to practice.Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis.HPV vaccine: One, two, or three doses for cervical cancer prevention?Progress and prospects for L2-based human papillomavirus vaccinesTransforming Cancer Prevention through Precision Medicine and Immune-oncology.Comparison of Two Widely Used Human Papillomavirus Detection and Genotyping Methods, GP5+/6+-Based PCR Followed by Reverse Line Blot Hybridization and Multiplex Type-Specific E7-Based PCR.Less than 3 doses of the HPV vaccine - Review of efficacy against virological and disease end points.An exploration of individual- and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girlsAwareness and knowledge of Human Papillomavirus (HPV), HPV-related cancers, and HPV vaccines in an uninsured adult clinic population.Change in Pattern of Secondary Cancers After Kaposi Sarcoma in the Era of Antiretroviral Therapy.Projected impact of HPV vaccination and primary HPV screening on cervical adenocarcinoma: Example from Australia.Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials.The whole story: a systematic review of economic evaluations of HPV vaccination including non-cervical HPV-associated diseases.Developments in L2-based human papillomavirus (HPV) vaccines.Progress in HPV vaccination in low- and lower-middle-income countries.Primary Immunization of Human Papillomavirus Vaccine in the Pediatric Population: What Is the Verdict Now?Tumour virus vaccines: hepatitis B virus and human papillomavirus.Impact of Number of Human Papillomavirus Vaccine Doses on Genital Warts Diagnoses Among a National Cohort of U.S. Adolescents.Younger age at initiation of the human papillomavirus (HPV) vaccination series is associated with higher rates of on-time completion.Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial.Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline.Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development.Explanations for the high potency of HPV prophylactic vaccines.A Retrospective and Prospective Look at Strategies to Increase Adolescent HPV Vaccine Uptake in the United States.Use of a 2-Dose Schedule for Human Papillomavirus Vaccination-Updated Recommendations of the Advisory Committee on Immunization Practices.Human papillomavirus vaccine for cancer cervix prevention: Rationale & recommendations for implementation in India.Are two doses of human papillomavirus vaccine sufficient for girls aged 15-18 years? Results from a cohort study in India.Human papilloma virus: global research architecture assessed by density-equalizing mapping.Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible countryAge-Structured Population Modeling of HPV-related Cervical Cancer in Texas and USEarly use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact
P2860
Q28079776-9705D214-744F-4EC6-9DB1-EB328CAE5AE2Q30251868-6491A060-9D1A-4B41-9565-D613D7E3BCAAQ33842040-C59EC75F-8913-4811-A5A2-C8BC9697BAA0Q36237280-A16AA6D1-21C4-4C56-8DA1-A661494C0494Q36457994-F6B5E7F8-8482-4EDF-A0B3-46BDA90510EEQ37014047-B43086A5-FC35-4EC4-9934-91C24D1B8C20Q37114360-2149C073-53FF-4811-8E20-2C2478E82971Q37132091-9E481D79-DD38-4933-B9DB-4ED93F3E0D23Q37135074-C39F3468-F1C1-4A97-927F-B3260A2CCF46Q37135276-1D1EAE84-F7C3-4A7B-8AF1-EC96620B0916Q37430038-990DE4B1-4D34-49A5-9AAF-4A3D699D3723Q38610032-D730DB8C-B408-4433-B78F-DF5BAEE8223FQ38655636-EB45C02F-AAED-433A-AA13-D24F45C3F3F1Q38673370-5F75553E-95AD-488B-8DCE-17A1FB53DE2DQ38997255-C1A4F8AD-73A6-45D1-A24F-A530B1364B29Q39021001-79A2C003-F989-406A-BC75-EC0B6A22B6C8Q39158741-1604E030-B702-4BC3-8CB7-5166853793D0Q39306396-A3A0CB61-437A-4A9E-8D2C-3C59D57B1B00Q40046649-0753A2A1-B9B4-4EE6-8618-D4D126357C84Q40215017-E05FF478-2141-467B-BCF8-5CE8E7B9F17CQ40878643-A8992A10-49AA-4893-96B0-29B2E1C7D899Q41929232-A3D654AF-51CE-455D-8143-F4837D59B922Q47111040-36A8D3F2-8C27-4EA5-B727-6580FF852FC9Q47549756-F06D7ADB-28DC-452E-98A6-8FEC3F92A67EQ47554977-CA842D13-20A8-40DC-933F-4BC9DD935DD9Q47717596-D2879043-F993-44BB-A38B-06A3F630BC8FQ47874062-01C2205C-9AAE-40EA-A662-4A5E7A94887DQ49537306-8A33264D-9BFB-4984-A0EB-90E582D4E470Q52631712-59FE6B7D-29F3-49F7-9D3E-049A7D27B62EQ55175761-2C13F010-2E7F-4FBF-B162-8ABCFF57349FQ56910734-E3D107B9-8337-4E25-B869-7F6304855CD2Q57150864-F7A91483-2094-4820-A553-4A69C5C86FC1Q58799763-95C511C4-6B53-4119-AB97-32A5D2FDE23C
P2860
Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunogenicity and HPV infecti ...... ntre prospective cohort study.
@en
Immunogenicity and HPV infecti ...... ntre prospective cohort study.
@nl
type
label
Immunogenicity and HPV infecti ...... ntre prospective cohort study.
@en
Immunogenicity and HPV infecti ...... ntre prospective cohort study.
@nl
prefLabel
Immunogenicity and HPV infecti ...... ntre prospective cohort study.
@en
Immunogenicity and HPV infecti ...... ntre prospective cohort study.
@nl
P2093
P2860
P50
P1433
P1476
Immunogenicity and HPV infecti ...... ntre prospective cohort study.
@en
P2093
Alka Kriplani
Angelika Michel
Bhagwan M Nene
Eric Lucas
Eric Zomawia
Gauravi Mishra
Geeta Joshi
Indian HPV Vaccine Study Group
Janki Mohan Babu Vijayamma
Julia Butt
P2860
P356
10.1016/S1470-2045(15)00414-3
P577
2015-12-01T00:00:00Z